These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25128013)

  • 1. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
    Cicci JD; Buie L; Bates J; van Deventer H
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e207-11. PubMed ID: 25128013
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab for tumor-induced hypercalcemia complicated by renal failure.
    Bech A; de Boer H
    Ann Intern Med; 2012 Jun; 156(12):906-7. PubMed ID: 22711097
    [No Abstract]   [Full Text] [Related]  

  • 3. Denosumab for post-transplantation hypercalcemia in osteopetrosis.
    Shroff R; Beringer O; Rao K; Hofbauer LC; Schulz A
    N Engl J Med; 2012 Nov; 367(18):1766-7. PubMed ID: 23113501
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
    Freeman A; El-Amm J; Aragon-Ching JB
    Clin Genitourin Cancer; 2013 Dec; 11(4):e24-6. PubMed ID: 24007982
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter to the editor: denosumab for “resistant” hypercalcemia in patients with impaired renal function.
    Arampatzis S
    J Clin Endocrinol Metab; 2015 Jan; 100(1):L6. PubMed ID: 25559545
    [No Abstract]   [Full Text] [Related]  

  • 6. Denosumab may reduce hypercalcaemia after transplantation for osteopetrosis.
    BMJ; 2012 Nov; 345():e7477. PubMed ID: 23135199
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
    Bowyer SE; White AM; Ransom DT; Davidson JA
    Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
    [No Abstract]   [Full Text] [Related]  

  • 8. Denosumab for treatment of hypercalcemia of malignancy.
    Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
    Khoury N; Chang J; Gru AA; Whyte MP
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypercalcemia in myeloma].
    Abe M
    Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
    Booth KA; Hays CI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
    J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response letter to the editor.
    Hu M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):L7. PubMed ID: 25559546
    [No Abstract]   [Full Text] [Related]  

  • 14. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
    Boikos SA; Hammers HJ
    J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
    [No Abstract]   [Full Text] [Related]  

  • 15. [Refractory hypercalcemia in patient with lung cancer].
    Grzywacz A; Dziuk M; Niemczyk S
    Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
    Adhikaree J; Newby Y; Sundar S
    BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of denosumab for prevention of skeletal-related complications in multiple myeloma.
    Hageman K; Patel KC; Mace K; Cooper MR
    Ann Pharmacother; 2013; 47(7-8):1069-74. PubMed ID: 23780806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined calcitonin and oral phosphate treatment for hypercalcemia in multiple myeloma.
    Brautbar N; Luboshitzky R
    Arch Intern Med; 1977 Jul; 137(7):914-6. PubMed ID: 879932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
    Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
    QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
    [No Abstract]   [Full Text] [Related]  

  • 20. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Adhikaree J; Newby Y; Sundar S
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.